Tierarztl Prax Ausg G Grosstiere Nutztiere 2014; 42(05): 271-277
DOI: 10.1055/s-0038-1623238
Original Article
Schattauer GmbH

Caseous lymphadenitis in small ruminants in Egypt

Clinical, epidemiological and prophylactic aspectsVerkäsende Lymphadenitis bei kleinen Wiederkäuern in Ägypten. Klinische, epidemiologische und prophylaktische Aspekte
A. F. Oreiby
1   Animal Medicine Department, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt
,
Y. M. Hegazy
1   Animal Medicine Department, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt
,
S. A. Osman
1   Animal Medicine Department, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt
,
Y. M. Ghanem
1   Animal Medicine Department, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt
,
M. H. Al-Gaabary
1   Animal Medicine Department, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt
› Author Affiliations
Further Information

Publication History

Received: 10 January 2014

Accepted after revision: 26 June 2014

Publication Date:
05 January 2018 (online)

Summary

Objective: The aim of this study was to investigate the distribution of caseous lymphadenitis (CLA) among small ruminants in Egypt, identify risk factors associated with its occurrence and to analyze the efficacy of the vaccine for control of CLA. Material and methods: A total of 1206 sheep and 351 goats were examined clinically for CLA. The prevalence and the risk factors of CLA in small ruminant flocks were estimated and identified. Efficacy of the commercial vaccine Case-Bac (Colorado Serum Company, USA) was determined in a field study trial conducted on 15 CLA-free lambs. Follow-up of vaccination immune response was carried out using indirect ELISA. Results: Prevalence of superficial CLA was 6.7%. Clinically, CLA appeared as abscesses in superficial lymph nodes mostly of the head and neck. On the basis of a multivariate analysis which accounted for clustering at herd level, sheep were at risk of getting superficial CLA 3.5 times more than goats (p < 0.0001). Animals of fixed flocks were at risk of getting the superficial CLA 2 times more than animals in fixed-mobile flocks (p < 0.038). Serological follow-up indicated protective antibody titers for 6 months. In vaccinated animals clinical cases were not observed while they occurred among non-vaccinated sheep. Discussion: Prevalence of CLA varied among studied flocks even between those of the same breeding system due to complex and overlapping factors associated with each flock like introduction or culling rate of animals, care of shepherds or owners to deal with opened abscesses in addition to the average age of the animals within each flock. Breeding systems have observable effects on occurrence of CLA: infected sheep can transmit the infection to a large number of animals in a short period under the conditions of close contact and reduced air flow in covered sheds. Conclusion and clinical relevance: Infected small ruminants in fixed flocks represent a risk factor for CLA for healthy ones. The vaccine used in the study provides an effective protection against new in fections. So mass vaccination of small ruminants against CLA in Egypt has to be considered to minimize the disease prevalence.

Zusammenfassung

Ziel dieser Studie war, die Verteilung der Pseudotuberkulose (caseous lymphadenitis, CLA) bei kleinen Wiederkäuern in Ägypten zu ermitteln, Risikofaktoren für das Auftreten der CLA zu erkennen und die Wirksamkeit eines zugelassenen Impfstoffs zu untersuchen. Material und Methoden: Neben Errechnung der CLA-Prävalenz durch klinische Untersuchung von 1206 Schafen und 351 Ziegen wurden in betroffenen Herden Risikofaktoren identifiziert. Die Wirksamkeit des kommerziell erhältlichen Impfstoffs Case-Bac (Colorado Serum Company, USA) wurde im Rahmen einer Feldstudie mit 15 nicht mit CLA infizierten Lämmern überprüft. Die Untersuchung der Immunantwort erfolgte mittels indirektem ELISA-Test. Ergebnisse: Die Prävalenz der oberflächlichen CLA, die sich in Form abszedierender Lymphknoten überwiegend an Kopf und Hals darstellte, betrug 6,7%. Das Risiko, an der oberflächlichen Form der CLA zu erkranken, lag für Schafe 3,5 Mal höher als für Ziegen (p < 0,0001). Tiere in permanenter Stallhaltung erkrankten doppelt so häufig wie Tiere mit Weidegang (p < 0,038). Die Impfung der Lämmer führte zu schützenden Antikörpertitern für 6 Mona te. Keines der geimpften Tiere erkrankte im Untersuchungszeitraum, obwohl Neuerkrankungen unter den ungeimpften Tieren der Herde auftraten. Diskussion: Die Prävalenz der CLA variierte in den untersuchten Herden stark, selbst wenn die Tiere unter ähnlichen Bedingungen gehalten wurden. Dies liegt an zahlreichen Einflussfaktoren auf die Erregereinschleppung und -ausbreitung wie beispielsweise die Zahl der Zukäufe und Abgänge, die mehr oder weniger konsequente Absonderung oder Merzung erkrankter Tiere sowie der generellen Altersstruktur innerhalb der Herde. In besonderem Maß beeinflusst das Haltungssystem die Zahl der Neuerkrankungen: Befinden sich bereits infizierte Tiere in der Herde, tragen vor allem enger Tierkontakt und fehlende Luftbewegung in geschlossenen Ställen zu hohen Erkrankungsraten bei. Schlussfolgerung und klinische Relevanz: Infizierte kleine Wiederkäuer in geschlossenen Stallungen stellen das größte Risiko für eine hohe Prävalenz der CLA dar. Der in der Studie eingesetzte Impfstoff bietet einen effektiven Schutz vor Neuerkrankungen und sollte deshalb vermehrt zum Einsatz kommen.

 
  • References

  • 1 Al-Gaabary MH, Osman SA, Ahmed MS, Oreiby AF. Abattoir survey on caseous lymphadenitis in sheep and goats in Tanta, Egypt. Small Rumin Res 2010; 94: 117-124.
  • 2 Al-Gaabary MH, El-Sheikh WMA. Epidemiological, clinical and preventive studies on caseous lymphadenitis in sheep and goats at Gharbia governorate. 10th Sci. Cong. Fac. Vet. Med.. Assiut University; Egypt: 2002: 402-417.
  • 3 Al-Gaabary MH, Osman SA, Oreiby AF. Caseous lymphadenitis in sheep and goats: clinical, epidemiological and preventive studies. Small Rumin Res 2009; 87: 116-121.
  • 4 Alonso JL, Simon MC, Girones O, Muzquiz JL, Ortega C, Garcia J. The effect of experimental infection with Corynebacterium pseudotuberculosis on reproduction in adult ewes. Res Vet Sci 1992; 52: 267-272.
  • 5 Arsenault J, Girard C, Dubreuil P, Daignault D, Galarneau JR, Boisclair J, Simard C, Belanger D. Prevalence of and carcass condemnation from maedi-visna, paratuberculosis and caseous lymphadenitis in culled sheep from Quebec. Canadian Prev Vet Med 2003; 59: 67-81.
  • 6 Bailey A, Scott S. Diagnostic Microbiology. 8th edn.. St. Louis: Mosby; 1990
  • 7 Baird G, Synge B, Dercksen D. Survey of caseous lymphadenitis seroprevalence in British terminal sire sheep breeds. Vet Rec 2004; 154: 505-506.
  • 8 Baird GJ, Fontaine MC. Corynebacterium pseudotuberculosis and its role in Ovine Caseous Lymphadenitis. J Comp Pathol 2007; 137: 179-210.
  • 9 Brogden KA, Glenn JS, East N. A Corynebacterium pseudotuberculosis bacterin with muramyl dipeptide induces antibody titers, increase the time of onset and decreases naturally occurring external abscesses in sheep and goats. Small Rumin Res 1996; 19: 161-168.
  • 10 Brown CC, Olander HJ. Caseous lymphadenitis of goats and sheep a review. Vet Bull 1987; 57: 1-12.
  • 11 Bruere AN, West DM. Caseous lymphadenitis. In: The Sheep: Health, Disease and Production. Palmerston North: Massey University Press; 1990: 252-257.
  • 12 Chirino-Zarraga C, Scaramelli A, Rey-Valerion C. Bacteriological characterization of Corynebacterium pseudotuberculosis in Venezuelan goat flocks. Small Rumin Res 2006; 65: 170-175.
  • 13 Collins FM, Campbell SG. Immunity to intracellular bacteria. Vet Immunol Immunopathol 1982; 3: 5-66.
  • 14 Eggleton DG, Doidge CV, Middleton HD, Minty DW. Immunization against ovine caseous lymphadenitis: efficacy of monocomponent Corynebacterium pseudotuberculosis toxoid vaccine and combined clostridial-corynebacterial vaccines. Aust Vet J 1991; 68: 320-321.
  • 15 Fontaine MC, Baird G, Connor KM, Rudge K, Sales J, Donachie W. Vaccination confers significant protection of sheep against infection with a virulent United Kingdom strain of Corynebacterium pseudotuberculosis . Vaccine 2006; 24: 5986-5996.
  • 16 Fontaine MC, Baird GJ. Caseous lymphadenitis. Small Rumin Res 2008; 76: 42-48.
  • 17 Guimaraes AS, Seyffert N, Bastos BL, Portela RWD, Meyer R, Carmo FB, Cruz JCM, Mcculloch JA, Lage AP, Heinemann MB, Miyoshi A, Azevedo V, Gouveia AMG. Caseous lymphadenitis in sheep flocks of the state of Minas Gerais, Brazil: Prevalence and management surveys. Small Rumin Res 2009; 87: 86-91.
  • 18 House RW, Schousboe M, Allen JP, Grant CC. Corynebacterium ovis (pseudotuberculosis) lymphadenitis in a sheep farmer: a new occupational disease in New Zealand. NZ Med J 1986; 99: 659-662.
  • 19 Kaba J, Nowicki M, Frymus T, Nowicka D, Witkowski L, Szaluś-Jordanow O, Czopowicz M, Thrusfield M. Evaluation of the risk factors influencing the spread of caseous lymphadenitis in goat herds. Pol J Vet Sci 2011; 14 (02) 231-237.
  • 20 Kumar J, Tripathi BN, Kumar R, Sonawane GG, Dixit SK. Rapid detection of Corynebacterium pseudotuberculosis in clinical samples from sheep. Trop Anim Health Prod 2013; 45 (06) 1429-1435.
  • 21 Menzies PI, Hwang TI, Prescolt JF. Comparison of an interferon gamma to phospholipase D enzyme linked immunosorbent assay for diagnosis of Corynebacterium pseudotuberculosis infection in experimentally infected goats. Vet Microbiol 2004; 100: 129-137.
  • 22 O‘Reilly KM, Medley GF, Green LE. The control of Corynebacterium pseudotuberculosis infection in sheep flocks: a mathematical model of the impact of vaccination, serological testing, clinical examination and lancing of abscesses. Prev Vet Med 2010; 95 (1–2): 115-126.
  • 23 Paton MW, Mercy AR, Sutherland SS, Ellis TM, Duda SR. The effect of antibody to caseous lymphadenitis in ewes on the efficacy of vaccination in lambs. Aust Vet J 1991; 68 (04) 143-146.
  • 24 Paton MW, Rose I, Hart R, Sutherland S, Mercy A, Ellis T. Postshearing management affects the sero-incidence of Corynebacterium pseudotuberculosis infection in sheep flocks. Prev Vet Med 1996; 26: 275-284.
  • 25 Paton MW. Control of cheesy gland in sheep. West Aust J Agric 1993; 34: 31-37.
  • 26 Paton MW. In: Decreasing the prevalence of caseous lymphadenitis in sheep. report to the Australian meat research Corporation; P.O. Box AA 498, Sydney South, NSW 2000 Australia: 1992: 2-3.
  • 27 Paton MW. The epidemiology and control of caseous lymphadenitis in Australian sheep flocks. Ph. D. Thesis School of Veterinary and Biochemical Sciences. Murdoch University; 2010
  • 28 Pepin M, Sanchis R, Paton M. La linfoadenite caseosa dei gliovinie et dei caprini. Suma 1999; 6: 53-61.
  • 29 Rosenberger G, Dirksen HD, Grunert E, Krause D, Stober M, Mack R. Clinical examination of cattle. 1st ed.. Berlin, Hamburg: Parey; 1979
  • 30 Seyffert N, Guimaraes AS, Pacheco LGC, Portela RW, Bastos BL, Dorella FA, Heinemann MB, Lage AP, Gouveia AMG, Meyer R, Miyoshi A, Azevedo V. High seroprevalence of caseous lymphadenitis in Barazalian goat herds revealed by Corynebacterium pseudotuberculosis secreted proteins based ELISA. Res Vet Sci 2010; 88: 50-55.
  • 31 Sunil V. Control of caseous lymphadenitis in sheep: Risk factors for disease and validation of an interferon gamma assay. M. V. Sc. Thesis Faculty of Graduate studies of the University of Guelph; 2006
  • 32 Valli VEO, Parry BW. Caseous lymphadenitis. In: Pathology of Domestic Animals. Vol. 3 4th edn.. Jubb KVF, Kennedy PC, Palmer N. eds. San Diego: Academic Press; 1993: 238-240.
  • 33 Williamson LH. Caseous lymphadenitis in small ruminants. Vet Clin North Am Food Anim Pract 2001; 17: 359-371.
  • 34 Windsor PA. Control of caseous lymphadenitis. Vet Clin North Am Food Anim Pract 2011; 27 (01) 193-202.
  • 35 Zaitoun AM, Ali HS. Clinical and experimental pseudotuberculosis on a multiple ages sheep and goats flock with control trials via treatment and BCG vaccination. Assiut Vet Med J 1999; 42: 239-259.